China’s life sciences sector, hereafter referred as LS sector, has transitioned into a globally significant innovation hub, underpinned by accelerated regulatory pathways, strong policy support, and rapidly rising R&D efficiency across pharmaceuticals, medical devices, and biotechnology.
Digital technologies—AI, robotics, and smart manufacturing—are reshaping the value chain, improving speed, scalability, and cost efficiency.
The sector is poised to deepen its role as a global R&D hub, with growth driven by advanced technologies and global partnerships.
